Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

Memorial Sloan Kettering Cancer Center

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1884-01-01

Employees: 10K

Market Cap: -

Website: http://www.mskcc.org

Clinical Trials

Supervised Aerobic Training During or After Chemotherapy for Operable Breast Cancer

Not Applicable

Active, not recruiting

Conditions: Breast Cancer

Interventions: Behavioral: Aerobic Training
Behavioral: Educational Information
Behavioral: Supervised Home Based Training

First Posted Date: 2013-09-17

Last Posted Date: 2024-07-26

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 144

Registration Number: NCT01943695

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Hepatic Arterial Infusion With Floxuridine and Dexamethasone in Combination With Gemcitabine as Adjuvant Treatment After Resection of Intrahepatic Cholangiocarcinoma

Phase 1

Completed

Conditions: Intrahepatic Cholangiocarcinoma
Peripheral Cholangiocarcinoma
Cholangiocellular Carcinoma) (ICC)
Cholangiolar Carcinoma

Interventions: Procedure: Liver resection and placement of hepatic artery infusion pump
Drug: FLOXURIDINE
Drug: DEXAMETHASONE
Drug: GEMCITABINE

First Posted Date: 2013-09-10

Last Posted Date: 2020-09-11

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 8

Registration Number: NCT01938729

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center at Commack, Commack, New York, United States
🇺🇸
Memorial Sloan Kettering Cancer Center at Basking Ridge, Basking Ridge, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

and more 2 locations

Study of Prophylactic Topical Dapsone 5% Gel Versus Moisturizer for Cetuximab-induced Papulopustular (Acneiform) Rash in Patients With mCRC or HNSCC Without Previous or Concurrent RT

Phase 3

Completed

Conditions: Metastatic Colorectal Cancer or Head and Neck Squamous Cell Carcinoma
Cetuximab-induced Papulopustular (Acneiform) Rash Who Have

Interventions: Drug: Topical Dapsone 5% Gel
Other: Moisturizer
Drug: oral antibiotics

First Posted Date: 2013-08-29

Last Posted Date: 2017-01-13

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 11

Registration Number: NCT01931150

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

A Novel "Pediatric-Inspired" Regimen with Reduced Myelosuppressive Drugs for Adults (aged 18-60) with Newly Diagnosed Ph Negative Acute Lymphoblastic Leukemia

Phase 2

Active, not recruiting

Conditions: Leukemia

Interventions: Drug: Daunorubicin
Drug: Vincristine
Drug: Prednisone
Drug: PEG-Asparaginase
Drug: Methotrexate
Drug: 6-MP (6-Mercaptopurine)
Drug: Cyclophosphamide
Drug: Cytarabine
Drug: Leucovorin
Drug: Dexamethasone
Other: Blood draw
Device: CT/PET scans

First Posted Date: 2013-08-12

Last Posted Date: 2025-02-28

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 39

Registration Number: NCT01920737

Locations: 🇺🇸
Weill Cornell Medical Center, New York, New York, United States
🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸
Duke University Medical Center, Durham, North Carolina, United States

and more 1 locations

Response Adapted Therapy With Bortezomib/Dexamethasone Followed by Addition of Lenalidomide in Non Responders as Initial Treatment for Patients With Multiple Myeloma

Phase 2

Completed

Conditions: Multiple Myeloma (MM)

Interventions: Drug: Bortezomib
Drug: Dexamethasone
Drug: Lenalidomide

First Posted Date: 2013-08-08

Last Posted Date: 2024-05-22

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 30

Registration Number: NCT01919086

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸
Hartford Healthcare Cancer Institute @ Hartford Hospital, Hartford, Connecticut, United States
🇺🇸
Memorial Sloan Kettering Cancer Center @ Suffolk, Commack, New York, United States

and more 3 locations

Quit IT: Development of a Web-based, 3D Coping Skills Game to Increase Self-Efficacy for Maintaining Smoking Abstinence Following Hospitalization

Not Applicable

Completed

Conditions: Tobacco Use Cessation

Interventions: Other: web-based video game (Quit IT)
Behavioral: Questionnaires
Behavioral: Evaluation Interview

First Posted Date: 2013-08-05

Last Posted Date: 2014-12-11

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 20

Registration Number: NCT01915836

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Study of Gemcitabine, Carboplatin, and Panitumumab (GCaP) as Neoadjuvant Chemotherapy in Patients With Muscle-Invasive Bladder Cancer

Phase 2

Terminated

Conditions: Bladder Cancer

Interventions: Drug: Gemcitabine
Drug: Carboplatin
Drug: Panitumumab
Procedure: radical cystectomy

First Posted Date: 2013-08-05

Last Posted Date: 2016-02-12

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 4

Registration Number: NCT01916109

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸
Memorial Sloan Kettering at Mercy Medical Center, Rockville Centre, New York, United States
🇺🇸
Memorial Sloan Kettering Cancer Center @ Suffolk, Commack, New York, United States

and more 2 locations

PET Imaging of Cancer Patients Using [18F]-SKI-249380, a Radiolabeled Dasatinib-Derivative

Phase 1

Completed

Conditions: Sarcoma
Melanoma
Carcinoma
Myeloma
Lymphoma

Interventions: Radiation: [18F]-SKI-249380
Procedure: PET/CT scan
Other: Blood draws

First Posted Date: 2013-08-05

Last Posted Date: 2020-04-27

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 11

Registration Number: NCT01916135

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Fluorestradiol (FES) PET/CT for Imaging Estrogen Receptor Status

Early Phase 1

Completed

Conditions: Breast Cancer

Interventions: Drug: Fluorestradiol (FES)
Procedure: PET/CT Imaging

First Posted Date: 2013-08-05

Last Posted Date: 2024-04-05

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 54

Registration Number: NCT01916122

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

FOLFOX Plus Regorafenib in Patients With Unresectable or Metastatic Esophagogastric Cancer

Phase 2

Completed

Conditions: Esophageal Cancer
Gastric Cancer

Interventions: Drug: Regorafenib
Drug: 5-Fluorouracil
Drug: Leucovorin
Drug: Oxaliplatin

First Posted Date: 2013-08-01

Last Posted Date: 2020-05-15

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 39

Registration Number: NCT01913639

Locations: 🇺🇸
Memoral Sloan Kettering Cancer Center, Basking Ridge, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Cancer Center @ Suffolk, Commack, New York, United States
🇺🇸
Memorial Sloan Kettering at Mercy Medical Center, Rockville Centre, New York, United States

and more 2 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy